Lesson
Define the Operative Exposure Window
Perioperative prophylaxis is a prevention intervention. Its pharmacologic target is effective tissue exposure when organisms enter the field, maintained through closure, with sterile practice and source control doing work an antibiotic cannot replace.
- Prevention
- Incision
- Tissue exposure
- Source control
- SSI endpoint
Define the procedure, host, organisms, and prevention bundle.
Reach effective tissue concentration before contamination.
Redose when time or blood loss threatens exposure.
End prophylaxis unless a treatment diagnosis exists.
Start with the indication
Clean procedures without an implant may not need systemic prophylaxis. Clean procedures with prosthetic material, clean-contaminated operations, and selected contaminated operations commonly do because infection would carry meaningful risk.
Separate prevention from treatment
Purulence, perforation, an infected field, or another established syndrome can require therapeutic antibiotics and source control. Extending a prophylaxis order does not create a complete treatment plan.
Name the exposure target
The dose should create adequate serum and tissue concentration before incision and preserve it while the wound is open. Timing, distribution, blood loss, and operative duration are therefore part of the drug.
Keep the full bundle visible
Skin preparation, hand preparation, sterile technique, temperature, glycemic management, oxygenation decisions, tissue handling, device care, and follow-up influence SSI risk independently of the antimicrobial order.
Quick check
Lesson
Let the Operative Field Define the Spectrum
Procedure anatomy predicts the organisms likely to enter the wound. Cefazolin-centered prevention fits many skin-flora operations, while bowel entry requires added aerobic gram-negative and anaerobic activity.
- Skin flora
- Bowel flora
- Implants
- Wound class
- Local epidemiology
Cefazolin centers susceptible staphylococci and streptococci.
Add aerobic gram-negative and anaerobic coverage.
Preserve strong antistaphylococcal prevention.
Use procedure-specific surveillance, not vague fear.
Use anatomy as the first filter
Skin incision introduces susceptible staphylococci and streptococci. Entry into colon, biliary tract, genital tract, urinary tract, mouth, or another colonized space changes the expected inoculum.
Respect prosthetic material
An implant raises the consequence of staphylococcal contamination and biofilm. It does not automatically justify broad gram-negative or anaerobic therapy when the field does not introduce those organisms.
Use wound classification carefully
Clean, clean-contaminated, contaminated, and dirty or infected describe increasing microbial burden, but the actual anatomy and intraoperative findings determine whether the plan remains prophylaxis or becomes treatment.
Refine with valid local data
Procedure-specific SSI organisms and susceptibility trends can update a protocol. A vague impression that resistance is common is not enough to justify universal vancomycin or expanded spectrum.
Quick check
Lesson
Build Timing Around Incision, Not the Order Entry
Most prophylactic agents begin within 60 minutes before incision. Vancomycin and fluoroquinolones may begin within 120 minutes because their infusion takes longer, but the actual dose and safe rate determine when administration must start.
- Sixty minutes
- One hundred twenty minutes
- Infusion completion
- Tourniquet
- Case delay
Most agents begin close enough to incision for useful exposure.
Vancomycin and fluoroquinolones need more time.
Deliver drug before blood flow is isolated.
A changed incision time can require a new plan.
Use the standard window
For most agents, begin administration within one hour before incision. The operational goal is meaningful tissue exposure when the incision is made, not merely a signed medication record.
Protect long infusions
Vancomycin and fluoroquinolones can start within two hours before incision. A large vancomycin dose delivered at no more than 10 mg per minute can require more than two hours, so the team may need to start earlier to finish safely.
Account for tourniquet isolation
When a limb tourniquet will reduce blood flow, complete the relevant systemic prophylaxis before inflation when feasible. Drug started afterward may not reach the isolated tissue reliably.
Respond to delay
If incision is postponed, compare the new start time with administration time, half-life, redose interval, and protocol. A once-timely dose can become too early.
Quick check
Lesson
Maintain Exposure Through Weight, Time, and Blood Loss
A full preincision dose creates the initial exposure. Weight can change that dose, elapsed time and major blood loss can trigger redosing, and repeated exposure requires more renal and toxicity attention than one loading dose.
- Cefazolin 2 g
- Cefazolin 3 g
- Four-hour redose
- Major blood loss
- Vancomycin rate
Cefazolin commonly increases at 120 kg.
Redose cefazolin from the first administration time.
Loss of circulating drug can trigger an early redose.
Vancomycin dose determines its minimum infusion time.
Use the conventional weight threshold
Common adult guidance uses cefazolin 2 g for patients below 120 kg and 3 g at 120 kg or more. Follow the current institutional protocol when pediatric age, extreme size, or procedure-specific evidence changes the pathway.
Redose from administration
Cefazolin is commonly redosed four hours after the preoperative dose when the operation remains open. The clock begins when the first dose was administered, not when incision occurred.
Respond to volume loss
Blood loss greater than about 1,500 mL can remove circulating drug and justify earlier redosing. Replacement volume, hemodynamics, agent, time, and expected closure all inform the decision.
Calculate vancomycin completely
When selected, vancomycin is commonly dosed at 15 mg/kg. Dividing the rounded milligram dose by 10 mg per minute gives the minimum infusion time needed to reduce infusion-reaction risk.
Quick check
Lesson
Keep Cefazolin First-Line Until the Procedure Demands More
Cefazolin offers focused susceptible skin-flora coverage, useful tissue exposure, and efficient administration. Broader agents are added or substituted only when anatomy, colonization, allergy, organism data, or an active infection creates a reason.
- Cefazolin
- MSSA
- Spectrum extension
- Therapeutic antibiotics
- Evidence conflict
Reliable susceptible skin-flora coverage for many procedures.
Add coverage only for organisms the field introduces.
Avoid both procedural gaps and duplicate exposure.
Expose conflicts and follow governed evidence.
Preserve the default
For many cardiac, vascular, orthopedic, and other clean operations, cefazolin is preferred because it aligns with common susceptible staphylococci and streptococci. Vancomycin does not improve that match simply by being broader.
Extend spectrum deliberately
Gastrointestinal or other clean-contaminated procedures can require gram-negative and anaerobic activity. Choose a validated combination or single-agent pathway rather than assembling untested breadth.
Reconcile existing treatment
A patient already receiving antibiotics may or may not have complete procedure coverage at incision. Compare spectrum, dose, tissue exposure, administration time, and expected organisms before adding another agent.
Expose the source conflict
The 2026 cefazolin label describes postoperative dosing for 24 hours. The 2022 SSI update recommends stopping at incisional closure because later prophylactic doses do not reduce SSI and add harm. Current evidence-based institutional policy should reconcile the difference.
Quick check
Lesson
Replace the Allergy Label with a Reaction Phenotype
A reported beta-lactam allergy can unnecessarily displace cefazolin. The clinically useful history identifies the exact drug, reaction timing, symptoms, severity, treatment, and later tolerated beta-lactams.
- Intolerance
- Immediate allergy
- Severe delayed reaction
- Side-chain similarity
- Cefazolin
Identify the exact drug and later tolerated agents.
Immediate and delayed patterns imply different risks.
Separate intolerance, urticaria, anaphylaxis, and SCAR.
Preserve cefazolin when the evaluated risk permits.
Separate intolerance from immunity
Nausea, headache, family history, yeast infection, and an unknown remote label are not equivalent to urticaria, bronchospasm, hypotension, or anaphylaxis.
Identify severe delayed disease
SJS, TEN, DRESS, acute generalized exanthematous pustulosis, hemolysis, nephritis, hepatitis, cytopenia, or another organ injury changes the avoidance and consultation pathway.
Use molecular context
Cefazolin has distinct side chains and can often be used in people carrying a penicillin allergy label when the phenotype and institutional algorithm permit. A fixed ten percent cross-reactivity shortcut is obsolete.
Compare the alternative harms
Clindamycin and vancomycin can introduce less reliable MSSA prevention, resistance, C. difficile risk, nephrotoxicity, longer infusion, and timing failure. They should not be called equivalent without analysis.
Quick check
Lesson
Use MRSA Coverage Only Inside a Defined Prevention Strategy
Routine vancomycin prophylaxis is not recommended. Known MRSA colonization, especially with prosthetic material, or a proven MRSA SSI outbreak can justify a protocol-based strategy that preserves all other needed coverage.
- MRSA screen
- Vancomycin
- MSSA
- Mupirocin
- Chlorhexidine
A current screen can identify a high-risk reservoir.
Pair an antistaphylococcal nasal agent with antisepsis.
Vancomycin does not replace every other spectrum need.
Track adherence, outcomes, tolerance, and selection.
Reserve systemic MRSA coverage
A current positive screen or prior MRSA history can support vancomycin consideration under protocol. A nonspecific belief that MRSA is common does not justify routine use.
Do not erase cefazolin
Vancomycin is less effective than cefazolin for susceptible S. aureus prevention and lacks gram-negative activity. It may supplement rather than replace the procedure's first-line regimen.
Decolonize the relevant reservoirs
Current SSI guidance supports an antistaphylococcal nasal agent with chlorhexidine skin antisepsis for orthopedic and cardiothoracic procedures and selected other high-risk prosthetic operations.
Monitor the program
Track completion, nasal and skin tolerance, SSI, MRSA, mupirocin susceptibility where relevant, recolonization, and protocol adherence. Decolonization is not indefinite hygiene.
Quick check
Lesson
Coordinate the Elective Colorectal Bundle
Current SSI guidance treats combined parenteral and oral antimicrobial prophylaxis before elective colorectal surgery as an essential practice. Mechanical preparation supports the pathway but is not an antimicrobial substitute.
- Oral antibiotics
- Parenteral prophylaxis
- Mechanical preparation
- Anaerobes
- Gram-negative organisms
Oral antibiotics act before the operative exposure.
Preparation supports the combined pathway.
Parenteral prophylaxis remains necessary.
Unexpected contamination can create a treatment diagnosis.
Combine rather than substitute
Oral antibiotics reduce bowel organism burden before surgery. Parenteral prophylaxis creates systemic and tissue exposure at incision. Completion of one does not cancel the other.
Cover the expected flora
The parenteral regimen must address skin flora plus aerobic gram-negative and anaerobic bowel organisms. Cefazolin plus metronidazole, selected cephamycins, and other protocol options are not assumed interchangeable without local review.
Place mechanical preparation correctly
Mechanical bowel preparation can support the combined regimen, but mechanical preparation alone does not provide the antimicrobial effect required for SSI prevention.
Adapt to operative reality
Unexpected gross contamination, perforation, abscess, or established infection changes the diagnosis. The postoperative plan then follows source control, cultures, severity, and therapeutic-duration principles.
Quick check
Lesson
Stop Prophylaxis at Closure
The 2022 SSI update recommends discontinuing prophylaxis at incisional closure. Drains, catheters, prosthetic material, and fear of infection do not create evidence that postoperative prophylactic doses prevent SSI.
- Incisional closure
- Treatment indication
- Drains
- C. difficile
- Resistance
Current SSI guidance stops at incision closure.
Purulence or perforation requires a treatment plan.
A device alone does not justify antibiotics.
Avoid CDI, toxicity, resistance, and excess cost.
Use the modern stop point
Antimicrobial doses administered after closure have not reduced SSI in current evidence. Discontinuation at closure is more precise than the older within-24-hours standard.
Convert deliberately when infection exists
Purulence, perforation, devitalized infected tissue, positive operative findings, or another established syndrome can require treatment. Name that diagnosis rather than calling the course extended prophylaxis.
Remove the drain myth
A drain or catheter needs aseptic management, daily necessity review, and timely removal. Its presence alone is not a reason to continue systemic antibiotics.
Measure balancing harms
Postoperative excess increases C. difficile infection, adverse reactions, nephrotoxicity, resistance, workload, and cost. These outcomes belong beside SSI on the quality dashboard.
Quick check
Lesson
Make the Workflow Reliable Enough to Audit
A correct guideline fails if no one owns the dose, infusion, incision delay, redose, or stop. A high-reliability pathway assigns decisions across surgery, anesthesia, nursing, pharmacy, and infection prevention.
- Ownership
- Checklist
- Timestamps
- SSI surveillance
- Feedback
Name who verifies each decision and timestamp.
Resolve discrepancies before incision.
Track delivery, SSI, CDI, and adverse effects.
Improve the pathway with evidence, not reflexive breadth.
Assign each transition
Pharmacy can verify selection and dose, nursing can confirm access and administration, anesthesia can own completion and redosing, surgery can define procedure and contamination, and infection prevention can close the surveillance loop.
Use the pause before it matters
Before incision, verify patient, procedure, site, implant, weight, allergy phenotype, MRSA status, selected regimen, dose, actual completion, and redose trigger. Resolve discrepancies before contamination.
Measure the delivery system
Track indication, correct agent, dose, on-time exposure, redosing, stop at closure, exceptions, SSI, C. difficile, kidney injury, severe allergy, and resistant organisms with meaningful denominators.
Learn without reflexive breadth
A multidisciplinary SSI review should examine host, preparation, drug execution, sterile technique, glycemia, temperature, procedure, source control, and follow-up before changing the regimen.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 172 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- RxPrep 2023 Chapter 23, Infectious Diseases II: Bacterial Infections
- Strategies to Prevent Surgical Site Infections in Acute-Care Hospitals: 2022 Update
- Strategies to Prevent MRSA Transmission and Infection: 2022 Update
- Cefazolin for Injection Prescribing Information, revised February 2026
- Vancomycin Injection Prescribing Information